RhoVac names new chairman of the board
31 October 2019 -

Sweden-based RhoVac AB has named Gunnar Gardemyr as the chairman of the board, it was reported yesterday.

Gardemyr is to replace Mikael Orum, who is leaving the board and the role of chair of the board.

Gardemyr said, 'Rhovac is an exciting company with great commercial potential in the field of immunotherapy. The company has presented very promising data and there is a solid plan for the upcoming work. In addition, Rhovac has managed to attract highly qualified employees with a high level of commitment who consistently deliver according to plan. Rhovac addresses a major medical need in one of the most common types of cancer - prostate cancer - and the company has the opportunity to be the first company to prevent or limit prostate cancer metastases with immunotherapy. I look forward, together with the board and management, to pilot the company towards the next important clinical milestone.'